MaxCyte, Inc. Payments to Acquire Short-term Investments
MaxCyte, Inc. (MXCT) reported Payments to Acquire Short-term Investments of $255.09 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2024-03-12
- MaxCyte, Inc. payments to acquire short-term investments for the quarter ending 2023-06-30 was $47.14M.
- MaxCyte, Inc. payments to acquire short-term investments for the quarter ending 2023-03-31 was $57.81M.
- MaxCyte, Inc. payments to acquire short-term investments for the quarter ending 2022-12-31 was $77.40M, a 17.60% increase year-over-year.
- MaxCyte, Inc. payments to acquire short-term investments for the quarter ending 2022-09-30 was $81.99M, a 50.87% decline year-over-year.
- MaxCyte, Inc. payments to acquire short-term investments for fiscal 2023 was $255.09M, a 12.32% decline from fiscal 2022.
- MaxCyte, Inc. payments to acquire short-term investments for fiscal 2022 was $290.94M, a 8.28% increase from fiscal 2021.
- MaxCyte, Inc. payments to acquire short-term investments for fiscal 2021 was $268.68M, a 1093.84% increase from fiscal 2020.
- MaxCyte, Inc. payments to acquire short-term investments for fiscal 2020 was $22.51M, a 203.15% increase from fiscal 2019.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month | Payments to Acquire Short-term Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | $255.09M 10-K · filed 2024-03-12 | ||||
| 2023-06-30 | $47.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $104.96M 10-Q · filed 2023-08-09 | $182.36M derived: sum of 3 quarters · filed 2024-03-12 | $264.35M derived: sum of 4 quarters · filed 2024-03-12 | |
| 2023-03-31 | $57.81M 10-Q · filed 2023-05-10 | $135.21M derived: sum of 2 quarters · filed 2024-03-12 | $217.21M derived: sum of 3 quarters · filed 2024-03-12 | ||
| 2022-12-31 | $77.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $159.39M derived: sum of 2 quarters · filed 2024-03-12 | $290.94M 10-K · filed 2024-03-12 | $290.94M 10-K · filed 2023-03-15 | |
| 2022-09-30 | $81.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $213.54M 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $131.55M 10-Q · filed 2023-08-09 | ||||
| 2021-12-31 | $65.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $232.72M derived: sum of 2 quarters · filed 2023-03-15 | $268.68M 10-K · filed 2023-03-15 | ||
| 2021-09-30 | $166.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $202.87M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $35.96M 10-Q · filed 2022-08-10 | ||||
| 2020-12-31 | $5.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $21.50M derived: sum of 2 quarters · filed 2022-03-22 | $22.51M 10-K · filed 2022-03-22 | ||
| 2020-09-30 | $15.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $16.99M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $1.00M 10-Q · filed 2021-09-13 | ||||
| 2019-12-31 | $7.42M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |